TriSalus Life Sciences, Inc. ( NASDAQ: TLSI) Q3 2024 Earnings Conference Call November 14, 2024 9:00 AM ET Jim Young - Senior Vice President, Investor Relations & Treasurer Mary Szela - President & ...
Presented full dataset from first-in-human Phase 1a clinical trial demonstrating PMN310 was generally well-tolerated with monthly dosing and that PMN310 demonstrated CSF levels indicative of potential ...